Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: A systematic review of efficacy and safety data

Critical Reviews in Oncology/Hematology

Volumn 84, Issue 1, 2012, Pages 93-100

  Breccia, Massimo ^a   Tiribelli, Mario ^b   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Chronic myeloid leukemia; Elderly; Imatinib; Second generation TKIs

Indexed keywords

ALPHA INTERFERON; BUSULFAN; CYTARABINE; DASATINIB; GAMMA INTERFERON; HYDROXYUREA; IMATINIB; INTERFERON; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT ALPHA INTERFERON AD;

AGE DISTRIBUTION; AGING; ANEMIA; BLEEDING; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; HEART DISEASE; HEART INFARCTION; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; INFECTION; LEUKOPENIA; LOW DRUG DOSE; LUNG DISEASE; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; PATIENT COMPLIANCE; PERICARDIAL EFFUSION; PHASE 2 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; QT PROLONGATION; RASH; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; INTERFERONS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS;

EID: 84866490652     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.01.001     Document Type: Review

References (25)

1. Goldman J.M., Melo J.V. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med 2003, 349:1451-1464.
2. Hehlmann R., Hochhaus A., Baccarani M. Chronic myeloid leukaemia. Lancet 2007, 370:342-350. European LeukemiaNet.
3. Michor F., Iwasa Y., Nowak M.A. The age incidence of chronic myeloid leukemia can be explained by a one-mutation model. Proc Natl Acad Sci U S A 2006, 103:14931-14934.
4. Rohrbacher M., Berger U., Hochhaus A., et al. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia 2009, 23:602-604.
5. Harrison S.J., Johnson P.R.E., Holyoake T.L. The Scotland Leukemia Registry audit of incidence, diagnosis and clinical management of new patients with chronic myeloid leukemia in 1999 and 2000. Scott Med J 2004, 49:87-90.
6. Berger U., Maywald O., Pfirmann M., et al. Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. Leukemia 2005, 19:984-989.
7. Gonsalves W., Ganti A.K. Targeted ant-cancer therapy in the elderly. Crit Rev Oncol Hematol 2011, 78:227-242.
8. Kantarjian H., Keating M., McCredie K., et al. Old age is a sign of poor prognosis in patients with chronic myelogenous leukemia. Southern Med J 1988, 80:1233-1235.
9. Cortes J., Kantarjian H., O'Brien S., et al. Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older. Am J Med 1996, 100:452-455.
10. Hilbe W., Apfelbeck U., Fridrik M., et al. Interferon-alpha for the treatment of elderly patients with chronic myeloid leukemia. Leuk Res 1998, 22:881-886.
11. Berger U., Engelich G., Maywald O., et al. Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha. Leukemia 2003, 17:1820-1826.
12. Cortes J., Talpaz M., O'Brien S., et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 2003, 98:1105-1113.
13. Latagliata R., Breccia M., Carmosino I., et al. Elderly patients with Ph+ chronic myelogenous leukemia (CML): results off imatinib mesylate treatment. Leuk Res 2005, 29:287-291.
14. Rosti G., Iacobucci I., Bassi S., et al. Impact off age on the outcome off patients with chronic myeloid leukemia in late chronic phase: results off a phase II study off the GIMEMA CML Working Party. Haematologica 2007, 92:101-105.
15. Latagliata R., Breccia M., Carmosino I., et al. "Real-life" results of front-line treatment with imatinib in older patients (>65 years) with newly diagnosed chronic myelogenous leukemia. Leuk Res 2010, 34:1472-1475.
16. Pletsch N., Lauseker M., Saussele S., et al. Therapy with imatinib in elderly CML patients (>65 years) is well tolerated but cytogenetic and molecular remissions seem to be achieved later compared to younger patients. Haematologica 2009, 94:253. abst 0625.
17. Sanchez-Gujio F.M., Duran S., Galende J., et al. Evaluation of tolerability and efficacy on imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study. Leuk Res 2011, 35:1184-1187.
18. Gugliotta G., Castagnetti F., Palandri F., et al. Frontline imatinib treatment off chronic myeloid leukemia: no impact off age on outcome, a survey by the GIMEMA CML Working Party. Blood 2011, 117:5591-5599.
19. Hasford J., Baccarani M., Hoffmann V., et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011, 118:686-692.
20. Lipton J.H., le Coutre P.D., Wang J., et al. Nilotinib in elderly chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: efficacy and safety analysis. Blood 2008, 112:3233.
21. le Coutre P.D., Turkina A., Kim D.W., et al. Efficacy and safety off nilotinib in elderly patients with imatinib-resistant or intolerant chronic myeloid leukemia (CML) in chronic phase 8CP: a sub-analysis off the ENACT (Expanding nilotinib access in clinical trials) study. Blood 2009, 114:3286.
22. Latagliata R., Breccia M., Castagnetti F., et al. Dasatinib is safe and effective in unselected chronic myeloid leukemia elderly patients resistant/intolerant to imatinib. Leuk Res 2011, 35:1164-1169.
23. Breccia M., Latagliata R., Stagno F., et al. Charlson comorbidity index and adult comorbidity evaluation-27 might predict compliance and development of pleural effusions in elderly chronic myeloid leukemia patients treated with dasatinib after resistance/intolerance to imatinib. Haematologica 2011, 96:1457-1461.
24. Khoury H.J., Cortes J.E., Kantarjian H., et al. Safety and efficacy of dasatinib vs imatinib by baseline comorbidity in patients with chronic myeloid leukemia in chronic phase (CML-CP): analysis of the DASISION trial. Blood 2010, 116. abstr 3421.
25. Larson R.A., Bunworasate U., Turkina A.G., et al. Nilotinib shows safety and efficacy in older patients (<65 years) with newly diagnosed chronic myeloid leukemia in chronic phase comparable with that in younger patients with chronic myeloid leukemia in chronic phase: results from ENESTnd. Blood 2011, abstr 3768.